Successful treatment of intractable palmoplantar pruritus with ondansetron

Archives of Dermatology

Volumn 134, Issue 8, 1998, Pages 925-926

  Downs, Anthony M R ^a   Kennedy, Cameron T C ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE SULFATE; ONDANSETRON; SEROTONIN ANTAGONIST;

ACANTHOSIS; ADULT; ARTICLE; CASE REPORT; DROWSINESS; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KERATOSIS PALMOPLANTARIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; SKIN INFLAMMATION; SUMMER; VERTIGO;

EID: 0031904084     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.8.925     Document Type: Article

References (6)

1. Greaves MW, Wall PD. Pathophysiology of itching. Lancet. 1996;348:938-940.
2. Wilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52:773-794.
3. Schworer H, Hartmann H, Ramadori G. Relief of choleostatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain. 1995;61:33-37.
4. Arai L, Stayer S, Schwartz R, Dorsey A. The use of ondansetron to treat pruritus associated with intrathecal morphine in two paediatric patients. Paediatr Anaesth. 1996;6:337-339.
5. Schworer H, Ramadori G. Improvement of choleostatic pruritus by ondansetron [letter]. Lancet. 1993;341:1277.
6. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest Med. 1993;71:659-662.